Amyloid imaging: Past, present and future perspectives

作者：Villemagne Victor L^*

来源：Ageing Research Reviews, 2016, 30: 95-106.

DOI：10.1016/j.arr.2016.01.005

• Alzheimer's disease
• A beta
• Positron emission tomography
• Neurodegenerative disorders
• Brain imaging

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are A beta amyloid plaques, and tau neurofibrillary tangles, along dendritic and synaptic loss and reactive gliosis.
Functional and molecular neuroimaging techniques such as positron emission tomography (PET) using functional and molecular tracers, in conjuction with other A beta and tau biomarkers in CSF, are proving valuable in the differential diagnosis of AD, as well as in establishing disease prognosis. With the advent of new therapeutic strategies, there has been an increasing application of these techniques for the determination of A beta burden in vivo in the patient selection, evaluation of target engagement and assessment of the efficacy of therapeutic approaches aimed at reducing A beta in the brain.

• 出版日期2016-9